---
title: Clinidipine + Telmisartan
description: >-
  Clinidipine + Telmisartan is prescribed for the treatment of essential
  hypertension (high blood pressure) in patients whose blood pressure is not
  adequately controlled by monotherapy with either drug alone.  It belongs to
  the pharmacological class of antihypertensives.  The combination works by w...
is_banned: false
lastModified: '2025-09-22T17:22:08.830Z'
faqs:
  - q: >-
      What is the recommended dosage for Clinidipine + Telmisartan?**


      **A:**  The standard starting dose is one tablet of Clinidipine 10 mg +
      Telmisartan 40 mg once daily for adults. The dose may be increased to a
      maximum of two tablets per day if needed. It is not recommended for
      children.
    a: >-
      A:**  The standard starting dose is one tablet of Clinidipine 10 mg +
      Telmisartan 40 mg once daily for adults. The dose may be increased to a
      maximum of two tablets per day if needed. It is not recommended for
      children.
  - q: >-
      What are the common side effects?**


      **A:** The most common side effects include dizziness, headache,
      peripheral edema, fatigue, and flushing.
    a: >-
      A:** The most common side effects include dizziness, headache, peripheral
      edema, fatigue, and flushing.
  - q: >-
      What are the serious side effects that require immediate medical
      attention?**


      **A:** Angioedema (swelling of the face, lips, tongue, or throat), severe
      hypotension (low blood pressure), liver dysfunction, and acute renal
      failure are serious side effects that warrant immediate medical attention.
    a: >-
      A:** Angioedema (swelling of the face, lips, tongue, or throat), severe
      hypotension (low blood pressure), liver dysfunction, and acute renal
      failure are serious side effects that warrant immediate medical attention.
  - q: >-
      Can Clinidipine + Telmisartan be used during pregnancy?**


      **A:** It is contraindicated during the second and third trimesters of
      pregnancy due to the risk of fetal harm.  Consult a healthcare
      professional for advice if pregnancy is suspected or planned.
    a: >-
      A:** It is contraindicated during the second and third trimesters of
      pregnancy due to the risk of fetal harm.  Consult a healthcare
      professional for advice if pregnancy is suspected or planned.
  - q: >-
      Is it safe to take Clinidipine + Telmisartan while breastfeeding?**


      **A:** There is insufficient data to determine the safety of Clinidipine +
      Telmisartan during breastfeeding. It's best to avoid its use during
      breastfeeding.
    a: >-
      A:** There is insufficient data to determine the safety of Clinidipine +
      Telmisartan during breastfeeding. It's best to avoid its use during
      breastfeeding.
  - q: >-
      What are the potential drug interactions with Clinidipine + Telmisartan?**


      **A:** Clinidipine interacts with CYP3A4 inhibitors and inducers.
      Telmisartan interacts with other antihypertensives, NSAIDs, and
      potassium-sparing diuretics.
    a: >-
      A:** Clinidipine interacts with CYP3A4 inhibitors and inducers.
      Telmisartan interacts with other antihypertensives, NSAIDs, and
      potassium-sparing diuretics.
  - q: >-
      How does Clinidipine + Telmisartan affect the liver and kidneys?**


      **A:**  Clinidipine is metabolized by the liver and may require dose
      adjustment in patients with hepatic impairment. Telmisartan can affect
      renal function, especially in patients with pre-existing kidney disease. 
      Monitoring of liver and kidney function is necessary.
    a: >-
      A:**  Clinidipine is metabolized by the liver and may require dose
      adjustment in patients with hepatic impairment. Telmisartan can affect
      renal function, especially in patients with pre-existing kidney disease. 
      Monitoring of liver and kidney function is necessary.
  - q: >-
      Can Clinidipine + Telmisartan be used in elderly patients?**


      **A:** Elderly patients should generally start with a lower dose and be
      monitored carefully for side effects.  Dose adjustments may be needed
      based on renal function.
    a: >-
      A:** Elderly patients should generally start with a lower dose and be
      monitored carefully for side effects.  Dose adjustments may be needed
      based on renal function.
  - q: >-
      What should patients be advised regarding lifestyle modifications while
      taking this medication?**


      **A:**  Patients should be advised to adopt a healthy lifestyle, including
      a balanced diet, regular exercise, and limiting alcohol consumption.  They
      should also avoid grapefruit juice as it may interact with clinidipine.
    a: >-
      A:**  Patients should be advised to adopt a healthy lifestyle, including a
      balanced diet, regular exercise, and limiting alcohol consumption.  They
      should also avoid grapefruit juice as it may interact with clinidipine.
  - q: >-
      How should patients monitor their response to therapy?**


      **A:**  Patients should regularly monitor their blood pressure and report
      any unusual symptoms to their healthcare professional.  Regular medical
      check-ups are important to assess treatment efficacy and adjust dosages if
      needed.
    a: >-
      A:**  Patients should regularly monitor their blood pressure and report
      any unusual symptoms to their healthcare professional.  Regular medical
      check-ups are important to assess treatment efficacy and adjust dosages if
      needed.
---
## **Usage**

Clinidipine + Telmisartan is prescribed for the treatment of essential hypertension (high blood pressure) in patients whose blood pressure is not adequately controlled by monotherapy with either drug alone.  It belongs to the pharmacological class of antihypertensives.  The combination works by widening blood vessels and reducing blood volume, which lowers blood pressure.

## **Alternate Names**

There are no widely recognized alternate names for the combination itself. However, it is composed of two distinct drugs: Clinidipine (a calcium channel blocker) and Telmisartan (an angiotensin II receptor blocker).  Clinidipine + Telmisartan is marketed under various brand names, including Cilniblu-T and Telmistrum Trio.

## **How It Works**

**Pharmacodynamics:** Clinidipine blocks calcium channels in vascular smooth muscle, leading to vasodilation. Telmisartan blocks the angiotensin II receptor, preventing vasoconstriction and reducing aldosterone secretion (which lowers blood volume). The combination exhibits synergistic antihypertensive effects.

**Pharmacokinetics:**  Both drugs are orally administered and well-absorbed. Clinidipine is extensively metabolized by the liver (CYP3A4 enzyme), primarily via hepatic excretion, with a half-life of approximately 5-8 hrs. Telmisartan undergoes minimal metabolism and is primarily excreted unchanged in bile, with a half-life of about 24 hours.

**Mode of Action:** Clinidipine primarily acts by inhibiting calcium influx into vascular smooth muscle cells, leading to vasodilation. Telmisartan competitively binds to the angiotensin II type 1 receptor, inhibiting the effects of angiotensin II.

**Elimination Pathways:** Clinidipine is primarily eliminated via hepatic metabolism and biliary excretion.  Telmisartan is predominantly excreted unchanged in bile.

## **Dosage**


### **Standard Dosage**

#### **Adults:**

The usual starting dose is one tablet of Clinidipine 10 mg + Telmisartan 40 mg once daily. The dosage can be increased to a maximum of two tablets per day (Clinidipine 20mg + Telmisartan 80mg) if blood pressure is not adequately controlled after 2-4 weeks.

#### **Children:**

The safety and efficacy of Clinidipine + Telmisartan have not been established in children. Therefore, it is not recommended for pediatric use.


#### **Special Cases:**

* **Elderly Patients:**  Start with a lower dose and monitor closely for adverse effects. Dose adjustment may be necessary based on renal function.
* **Patients with Renal Impairment:**  Lower doses are recommended, especially in patients with severe renal impairment. Close monitoring is crucial.
* **Patients with Hepatic Dysfunction:**  Clinidipine dosage should be reduced in patients with moderate to severe hepatic impairment.  Telmisartan dosage adjustment may be necessary.
* **Patients with Comorbid Conditions:** Dosage adjustments might be necessary in patients with conditions such as diabetes or cardiovascular disease.  Careful monitoring is warranted.

### **Clinical Use Cases**

Clinidipine + Telmisartan is not indicated for use in clinical settings such as intubation, surgical procedures, mechanical ventilation, ICU use, or emergency situations. Its primary indication is the management of essential hypertension.


### **Dosage Adjustments**

Dose modifications are based on individual patient factors, primarily renal and hepatic function. It is essential to monitor blood pressure response and adjust the dose accordingly.

## **Side Effects**


### **Common Side Effects:**

Dizziness, headache, peripheral edema (swelling in the ankles or feet), fatigue, flushing.

### **Rare but Serious Side Effects:**

Angioedema (swelling of the face, lips, tongue, or throat), hypotension, liver dysfunction, renal failure, Stevens-Johnson syndrome.


### **Long-Term Effects:**

Potential long-term effects of chronic use are still being investigated.  However, long-term monitoring of renal function and electrolyte levels is recommended.

### **Adverse Drug Reactions (ADR):**

Clinically significant ADRs include angioedema, severe hypotension, and acute renal failure.


## **Contraindications**

* Hypersensitivity to either clinidipine or telmisartan.
* Cardiogenic shock, unstable angina, recent myocardial infarction.
* Severe aortic stenosis, heart failure.
* Second and third trimesters of pregnancy.
* Severe hepatic impairment, biliary obstructive disorders.
* Concomitant use of telmisartan with aliskiren in patients with diabetes or renal impairment.


## **Drug Interactions**

Clinidipine is metabolized by CYP3A4.  Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, erythromycin) may increase clinidipine levels.  CYP3A4 inducers (e.g., rifampin, phenytoin) may decrease its levels.  Telmisartan may interact with other antihypertensives, increasing the risk of hypotension.  Concurrent use with NSAIDs may decrease its antihypertensive effect and increase the risk of renal impairment. Potassium-sparing diuretics or potassium supplements can increase the risk of hyperkalemia when used with telmisartan.


## **Pregnancy and Breastfeeding**

Clinidipine + Telmisartan is contraindicated during the second and third trimesters of pregnancy due to potential fetal harm. It is not recommended during breastfeeding due to the lack of data on its safety.

## **Drug Profile Summary**

* **Mechanism of Action:** Clinidipine: Calcium channel blocker (vasodilation). Telmisartan: Angiotensin II receptor blocker (vasodilation, reduced aldosterone).
* **Side Effects:** Dizziness, headache, edema, fatigue, flushing.  Rarely: angioedema, hypotension, liver/renal dysfunction.
* **Contraindications:** Hypersensitivity, pregnancy (2nd/3rd trimester), severe hepatic/renal impairment, concomitant use of telmisartan with aliskiren in patients with diabetes or renal impairment.
* **Drug Interactions:** CYP3A4 inhibitors/inducers (clinidipine), other antihypertensives, NSAIDs, potassium-sparing diuretics (telmisartan).
* **Pregnancy & Breastfeeding:** Contraindicated in 2nd/3rd trimesters of pregnancy and not recommended during breastfeeding.
* **Dosage:** Adults: Clinidipine 10-20 mg + Telmisartan 40-80 mg once daily. Adjustments needed for renal/hepatic impairment.
* **Monitoring Parameters:** Blood pressure, renal function, electrolyte levels (especially potassium).

## **Popular Combinations**

Clinidipine + Telmisartan is sometimes used in combination with hydrochlorothiazide (a thiazide diuretic) for enhanced blood pressure control.  However, such combinations require careful monitoring for electrolyte imbalances and other adverse effects.


## **Precautions**

Assess renal and hepatic function, electrolyte levels, and history of hypersensitivity before initiating treatment. Closely monitor blood pressure and adjust dosage as needed.  Caution in patients with diabetes, cardiovascular disease, or other comorbidities.  Advise patients on potential side effects and drug interactions.  Avoid alcohol and grapefruit juice, which can interact with clinidipine.


## **FAQs (Frequently Asked Questions)**


### **Q1: What is the recommended dosage for Clinidipine + Telmisartan?**

**A:**  The standard starting dose is one tablet of Clinidipine 10 mg + Telmisartan 40 mg once daily for adults. The dose may be increased to a maximum of two tablets per day if needed. It is not recommended for children.


### **Q2:  What are the common side effects?**

**A:** The most common side effects include dizziness, headache, peripheral edema, fatigue, and flushing.

### **Q3:  What are the serious side effects that require immediate medical attention?**

**A:** Angioedema (swelling of the face, lips, tongue, or throat), severe hypotension (low blood pressure), liver dysfunction, and acute renal failure are serious side effects that warrant immediate medical attention.


### **Q4: Can Clinidipine + Telmisartan be used during pregnancy?**

**A:** It is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal harm.  Consult a healthcare professional for advice if pregnancy is suspected or planned.


### **Q5: Is it safe to take Clinidipine + Telmisartan while breastfeeding?**

**A:** There is insufficient data to determine the safety of Clinidipine + Telmisartan during breastfeeding. It's best to avoid its use during breastfeeding.


### **Q6: What are the potential drug interactions with Clinidipine + Telmisartan?**

**A:** Clinidipine interacts with CYP3A4 inhibitors and inducers. Telmisartan interacts with other antihypertensives, NSAIDs, and potassium-sparing diuretics.


### **Q7: How does Clinidipine + Telmisartan affect the liver and kidneys?**

**A:**  Clinidipine is metabolized by the liver and may require dose adjustment in patients with hepatic impairment. Telmisartan can affect renal function, especially in patients with pre-existing kidney disease.  Monitoring of liver and kidney function is necessary.


### **Q8: Can Clinidipine + Telmisartan be used in elderly patients?**

**A:** Elderly patients should generally start with a lower dose and be monitored carefully for side effects.  Dose adjustments may be needed based on renal function.


### **Q9: What should patients be advised regarding lifestyle modifications while taking this medication?**

**A:**  Patients should be advised to adopt a healthy lifestyle, including a balanced diet, regular exercise, and limiting alcohol consumption.  They should also avoid grapefruit juice as it may interact with clinidipine.


### **Q10: How should patients monitor their response to therapy?**

**A:**  Patients should regularly monitor their blood pressure and report any unusual symptoms to their healthcare professional.  Regular medical check-ups are important to assess treatment efficacy and adjust dosages if needed.

